Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Köhler, Jens ^a,d   Erlenkamp, German ^b   Eberlin, Adrien ^c   Rumpf, Tobias ^a   Slynko, Inna ^b   Metzger, Eric ^c   Schüle, Roland ^c   Sippl, Wolfgang ^a,b   Jung, Manfred ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HISTONE H3; LESTAURTINIB; MESSENGER RNA; PROTEIN KINASE C; PROTEIN KINASE C RELATED KINASE 1; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; CARBAZOLE DERIVATIVE; ENZYME INHIBITOR; HISTONE; PROTEIN KINASE N;

ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; GENE EXPRESSION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; CARBAZOLES; CELL LINE, TUMOR; CELLS, CULTURED; ENZYME INHIBITORS; GENE EXPRESSION; HISTONES; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE C; RECEPTORS, ANDROGEN;

EID: 84859979617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034973     Document Type: Article

References (42)

1. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A, (2009) An operational definition of epigenetics. Genes Dev 23: 781-783.
2. Handel AE, Ebers GC, Ramagopalan SV, (2009) Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med.
3. Papait R, Monti E, Bonapace IM, (2009) Novel approaches on epigenetics. Curr Opin Drug Discov Devel 12: 264-275.
4. Allis CD, Berger SL, Cote J, Dent S, Jenuwein T, et al. (2007) New nomenclature for chromatin-modifying enzymes. Cell 131: 633-636.
5. Perez Fidalgo JA, Roda D, Rosello S, Rodriguez-Braun E, Cervantes A, (2009) Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. Clin Transl Oncol 11: 787-798.
6. Markaki Y, Christogianni A, Politou AS, Georgatos SD, (2009) Phosphorylation of histone H3 at Thr3 is part of a combinatorial pattern that marks and configures mitotic chromatin. J Cell Sci 122: 2809-2819.
7. Patnaik D, Jun X, Glicksman MA, Cuny GD, Stein RL, et al. (2008) Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay. J Biomol Screen 13: 1025-1034.
8. Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, et al. (2010) Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 464: 792-796.
9. Metzger E, Yin N, Wissmann M, Kunowska N, Fischer K, et al. (2008) Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol 10: 53-60.
10. Hurd PJ, Bannister AJ, Halls K, Dawson MA, Vermeulen M, et al. (2009) Phosphorylation of histone H3 Thr-45 is linked to apoptosis. J Biol Chem 284: 16575-16583.
11. Gingrich DE, Hudkins RL, (2002) Synthesis and kinase inhibitory activity of 3′-(S)-epi-K-252a. Bioorg Med Chem Lett 12: 2829-2831.
12. Revill P, Serradell N, Bolos J, Rosa E, (2007) Lestaurtinib. Drugs Fut 32: 215.
13. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, et al. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671.
14. Shabbir M, Stuart R, (2010) Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs 19: 427-436.
15. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, et al. (2006) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108: 3262-3270.
16. Kufareva I, Abagyan R, (2008) Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. Journal of medicinal chemistry 51: 7921-7932.
17. Jones G, Willet P, Glen RC, Leach AR, Taylor R, (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748.
18. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of medicinal chemistry 47: 1739-1749.
19. Meier R, Pippel M, Brandt F, Sippl W, Baldauf C, (2010) ParaDockS: a framework for molecular docking with population-based metaheuristics. J Chem Inf Model 50: 879-889.
20. Case DA, Cheatham TEI, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
21. Case DA, Darden TA, Cheatham TEI, Simmerling CL, Wang J, et al. (2008) AMBER 10. San Francisco University of California.
22. Englebienne P, Moitessier N, (2009) Docking ligands into flexible and solvated macromolecules. 4. Are popular scoring functions accurate for this class of proteins? J Chem Inf Model 49: 1568-1580.
23. Charifson PS, Corkery JJ, Murcko MA, Walters WP, (1999) Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. Journal of medicinal chemistry 42: 5100-5109.
24. Sobel RE, Sadar MD, (2005) Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. The Journal of urology 173: 342-359.
25. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, et al. (2005) Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65: 1849-1857.
26. Frigo DE, Sherk AB, Wittmann BM, Norris JD, Wang Q, et al. (2009) Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol 23: 1385-1396.
27. Prescott JL, Blok L, Tindall DJ, (1998) Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate 35: 71-80.
28. Ma AH, Xia L, Desai SJ, Boucher DL, Guan Y, et al. (2006) Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells. Cancer Res 66: 8439-8447.
29. Ngan S, Stronach EA, Photiou A, Waxman J, Ali S, et al. (2009) Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 28: 2051-2063.
30. Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, et al. (2006) GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate 66: 886-894.
31. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, et al. (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437: 436-439.
32. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403-410.
33. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
34. Laskowski RA, MacArthur MW, Moss DS, Thornton JM, (1993) PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr 26: 283-291.
35. Case DA, Darden TA, Cheatham TEI, Simmerling CL, Wang J, et al. (2006) AMBER 9. San Francisco University of California.
36. Xu ZB, Chaudhary D, Olland S, Wolfrom S, Czerwinski R, et al. (2004) Catalytic domain crystal structure of protein kinase C-theta (PKCtheta). J Biol Chem 279: 50401-50409.
37. Shen YQ, Tang L, Zhou HM, Lin ZJ, (2001) Structure of human muscle creatine kinase. Acta Crystallogr D Biol Crystallogr 57: 1196-1200.
38. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
39. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157-1174.
40. Pastor RW, Brooks BR, Szabo A, (1988) An analysis of the accuracy of Langevin and molecular dynamics algorithms. Mol Phys 65: 1409-1419.
41. Ryckaert JP, Ciccotti G, Berendsen HJC, (1977) Numerical integration of the cartesian equations of motions of a system with constraints: Molecular dynamics of n-alkanes. J Comput Phys 23: 327-341.
42. Darden T, Pedersen L, (1993) Particle Mesh Ewald: an Nlog(N) method for Ewald sums in large systems. J Chem Phys 103: 8577-8593.